论文部分内容阅读
为了探索免疫组织化学技术在检测乳腺癌多药耐受表型中的价值，我们采用链霉菌抗生物素蛋白——过氧化物酶连结法（ＳＰ法）分析了６０例术前未经任何化学治疗的乳腺癌组织Ｐ－ｇｐ表达情况，１２例癌旁正常乳腺组织和８例乳腺良性肿瘤组织作为对照。结果发现：三种组织阳性率分别为：乳腺癌组７６．７％（４６／６０），癌旁正常乳腺组织１６．７％（２／１２），乳腺良性肿瘤２５．０％（２／８）。癌组织与其它两种组织相比，差异具有显著性（Ｐ＜０．００５）。并且，乳腺癌组织Ｐ－ｇｐ表达水平与提示乳腺癌疾病发展和预后的临床病理参数，如年龄、原发灶大小、淋巴结转移数、ＴＮＭ分期、病理学类型和组织学分级无关（Ｐ＞０．０５）。我们得出结论，多药耐受表型是与乳腺癌恶性表型同时发生的一种内在本质特征，并且其表达程度不受疾病发展的影响，Ｐ－ｇｐ免疫组化染色能够有效地检测乳腺癌多药耐受。
To explore the value of immunohistochemistry in the detection of multi-drug resistant phenotypes in breast cancer, we analyzed 60 patients without any chemical preoperatively using streptavidin-peroxidase ligation (SP method). The expression of P-gp in the treated breast cancer tissues was compared with 12 normal breast tissue adjacent to the cancer and 8 benign breast tumors. The results showed that the positive rates of the three tissues were: 76.7% (46/60) in the breast cancer group, 16.7% (2/12) in the adjacent normal breast tissue, and 25.0% in the benign breast tumor (2/8). ). The difference between cancer tissues and the other two tissues was significant (P < 0.005). Moreover, the expression level of P-gp in breast cancer tissues was not related to clinicopathological parameters such as age, primary tumor size, lymph node metastasis, TNM stage, pathological type, and histological grade, suggesting the development and prognosis of breast cancer disease (P>0 .05). We conclude that the multi-drug tolerance phenotype is an intrinsic essential feature that occurs concurrently with the malignant phenotype of breast cancer, and its degree of expression is not affected by disease progression. P-gp immunohistochemical staining can effectively detect the breast Multidrug resistance in cancer.